Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review

• Published in: Journal of child and adolescent psychopharmacology Vol. 31; no. 9; p. 578
• Main Authors: Dijk, Hermien H, Wessels, Lisa M, Constanti, Margaret, van den Hoofdakker, Barbara J, Hoekstra, Pieter J, Groenman, Annabeth P
• Format: Journal Article
• Language: English
• Published: United States 01.11.2021
• Subjects: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity - drug therapy; Central Nervous System Stimulants - therapeutic use; Child; Cost-Benefit Analysis; Humans; economic evaluations; cost-effectiveness; ADHD treatments; attention-deficit/hyperactivity disorder
• ISSN: 1557-8992
• DOI: 10.1089/cap.2021.0068

This systematic review provides an overview of full economic evaluations of attention-deficit/hyperactivity disorder (ADHD) treatments, evaluates their outcomes, and highlights gaps in the literature. Electronic databases were searched for full economic evaluations of ADHD treatments for children, adolescents, or adults published in English or Dutch. Twenty-nine studies met the inclusion criteria. Almost all studies that compared medication or psychosocial treatment to no treatment, placebo, or care as usual indicated that medication and psychosocial treatment were cost-effective compared to the control group. Stimulant treatment appeared to be cost-effective for the treatment of ADHD in children and adolescents. Only few studies focus on treatments in adults and psychosocial treatments and the number of studies with long time horizons and without industry funding is limited. Despite the rising interest in cost-effectiveness, this systematic review shows that more cost-effectiveness research of higher quality is warranted to aid in the optimal use of available treatments and resources for individuals with ADHD. Specifically, more studies should focus on treatments in adults and psychosocial treatments, and more studies with long time horizons and without industry funding are warranted. Nevertheless, we can conclude that treating ADHD is generally cost-effective compared to no treatment. PROSPERO: CRD42017060074. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=60074.